Health Catalyst’s (HCAT) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler restated their overweight rating on shares of Health Catalyst (NASDAQ:HCAT) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $12.00 price objective on the stock, up from their prior price objective of $11.00.

HCAT has been the topic of several other research reports. Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Stephens raised their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. boosted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Trading Down 0.2 %

NASDAQ:HCAT opened at $8.50 on Tuesday. The stock has a market cap of $517.23 million, a price-to-earnings ratio of -6.30 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The business has a fifty day moving average of $8.13 and a 200-day moving average of $7.29.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the company earned ($0.22) EPS. The business’s quarterly revenue was up 3.5% on a year-over-year basis. Equities analysts predict that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This trade represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,068 shares of company stock valued at $257,555. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

A number of institutional investors have recently bought and sold shares of HCAT. First Light Asset Management LLC raised its stake in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc raised its position in Health Catalyst by 16.4% during the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after acquiring an additional 360,201 shares in the last quarter. Millennium Management LLC raised its position in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA lifted its stake in Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Daventry Group LP increased its stake in shares of Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.